Abstract 1308P
Background
High false positive rates in LDCT screening are an important concern. The study aims to explore the diagnostic performance of different diameter thresholds for various lung nodules to reduce unnecessary follow-up LDCT scans and the waste of medical resources.
Methods
Participants were recruited from the "Guangzhou Lung-Care Project" at the First Affiliated Hospital of Guangzhou Medical University in China between 2017 and 2021. The average transverse diameter of lung nodules was measured by semi-automatic segmentation. Positive outcomes were divided into two groups: outcome 1-lung cancer diagnosis with AAH/AIS, and outcome 2-lung cancer diagnosis without AAH/AIS. We calculated the area under the receiver-operating characteristic curves (AUCs), sensitivity, specificity, positive prediction rate(ppv) and negative prediction rate (NPV) to evaluate the diagnostic performance of lung cancer under each threshold between 5mm to 10mm.
Results
In the first year after LDCT screening, 126 cases of lung cancer (including 13 cases of AAH/AIS) were diagnosed among the participants of 11,705 (5,425 men and 6,280 women; median age 59). Increase the average transverse diameter threshold from 5 to 7mm in all lung nodules (solid, part-solid, non-solid), and gradually increase the AUC in outcome 1 (0.766 to 0.825) and outcome 2 (0.78 to 0.839). From 7 to 10mm, the AUC in outcome 1 (0.825 to 0.764) and outcome 2 (0.839 to 0.778) is gradually reduced. In the outcome 2, when the diameter threshold was increased from 5mm to 8mm, the specificity (60.06% to 90.82%) and ppv (6.57% to 19.02%) increased significantly, the sensitivity was reduced (94.02% to 76.07%). When the diameter threshold was increased from 8mm to 10mm, the sensitivity was significantly reduced (76.07% to 60.68%) and specificity (90.82% to 94.88%) and ppv (19.02% to 25.13%) increased slightly. There is no obvious difference between outcome 1 and outcome 2 in the above indicators.
Conclusions
Our study demonstrates that setting a diameter threshold of 8mm for LDCT screening of lung nodules achieves better overall diagnostic performance, reducing false positives and unnecessary follow-up scans while minimizing medical resource waste.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Wenhua Liang.
Funding
The First Affiliated Hospital of Guangzhou Medical University; China State Key Laboratory of Respiratory Disease & National Clinical Research Center for Respiratory Disease.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
478P - Germline BRCA1/2 pathogenetic variants (gBRCA1/2 PV) affect outcome of hormone (HR)-positive HER2-negative metastatic breast cancer (MBC) patients (pts) treated with cyclin-dependent kinase 4/6 inhibitor (CDK 4/6i) plus endocrine therapy (ET): The BREAK study
Presenter: Antonella Palazzo
Session: Poster session 04
479P - Radiomics to predict HER2 status in breast cancer brain metastases
Presenter: Gaia Griguolo
Session: Poster session 04
480P - Prognostic significance of somatic DNA gene rearrangement and structural atypia in metastatic breast cancer
Presenter: Hiroshi Tada
Session: Poster session 04
481P - Second generation oral selective estrogen receptor degraders (SERDs) in breast cancer: A systematic review and meta-analysis of clinical trials
Presenter: Maysa Silveira Vilbert
Session: Poster session 04
482P - Precision imaging with human epidermal growth factor receptor 2-positron emission tomography (HER2-PET) for refined treatment selection in patients with HER2-low breast cancer
Presenter: Siri af Burén
Session: Poster session 04
483P - Prognostic value of androgen receptor expression in patients with advanced triple-negative metastatic breast cancer treated with sacituzumab govitecan: A French multicentre retrospective study
Presenter: Monica Arnedos
Session: Poster session 04
484P - Multi-platform characterization of HER2 expression in triple-negative breast cancer
Presenter: Ana C Garrido-Castro
Session: Poster session 04
485P - A novel approach to identify subpopulation of CTCs with metastatic potential using sc-RNA-seq
Presenter: Evgeniya Grigoryeva
Session: Poster session 04
486P - The influence of NF1 germline and somatic mutations on breast cancer patient survival
Presenter: Roope Kallionpää
Session: Poster session 04
487P - Induction of an inflammatory tumor microenvironment with oncolytic virus CF33-hNIS-antiPD-L1 intratumoral injection in patients with metastatic triple-negative breast cancer (mTNBC)
Presenter: Jamie Rand
Session: Poster session 04